Strength of evidence of non-inferiority trials-The adjustment of the type I error rate in non-inferiority trials with the synthesis method

In non‐inferiority trials that employ the synthesis method several types of dependencies among test statistics occur due to sharing of the same information from the historical trial. The conditions under which the dependencies appear may be divided into three categories. The first case is when a new...

Full description

Saved in:
Bibliographic Details
Published inStatistics in medicine Vol. 29; no. 14; pp. 1477 - 1487
Main Authors Kang, Seung-Ho, Tsong, Yi
Format Journal Article
LanguageEnglish
Published Chichester, UK John Wiley & Sons, Ltd 30.06.2010
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text
ISSN0277-6715
1097-0258
1097-0258
DOI10.1002/sim.3903

Cover

More Information
Summary:In non‐inferiority trials that employ the synthesis method several types of dependencies among test statistics occur due to sharing of the same information from the historical trial. The conditions under which the dependencies appear may be divided into three categories. The first case is when a new drug is approved with single non‐inferiority trial. The second case is when a new drug is approved if two independent non‐inferiority trials show positive results. The third case is when two new different drugs are approved with the same active control. The problem of the dependencies is that they can make the type I error rate deviate from the nominal level. In order to study such deviations, we introduce the unconditional and conditional across‐trial type I error rates when the non‐inferiority margin is estimated from the historical trial, and investigate how the dependencies affect the type I error rates. We show that the unconditional across‐trial type I error rate increases dramatically as does the correlation between two non‐inferiority tests when a new drug is approved based on the positive results of two non‐inferiority trials. We conclude that the conditional across‐trial type I error rate involves the unknown treatment effect in the historical trial. The formulae of the conditional across‐trial type I error rates provide us with a way of investigating the conditional across‐trial type I error rates for various assumed values of the treatment effect in the historical trial. Copyright © 2010 John Wiley & Sons, Ltd.
Bibliography:Korea Science & Engineering Foundation - No. R01-2007-000-20713-0
istex:38011ECE66BA01BA6051E8F45228D1D68CA4A884
ark:/67375/WNG-CP51Q6PH-W
This article represents the point of views of the authors. It does not necessarily represent the official position of U.S. FDA.
ArticleID:SIM3903
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ISSN:0277-6715
1097-0258
1097-0258
DOI:10.1002/sim.3903